Danielle Simmons, “Epigenetic Influences and Disease.” Nature Education 1(1):6, 2008

Alyson A. Lokken, Nancy J. Zeleznik-Le “Breaking the LSD1/KDM1A Addiction: Therapeutic Targeting of the Epigenetic Modifier in AML” Cancer Cell, Volume 21, Issue 4, 17 April 2012, pp 451-453

William J. Harris, Xu Huang, James T. Lynch, Gary J. Spencer, James R. Hitchin, Yaoyong Li, Filippo Ciceri, Julian G. Blaser, Brigit F. Greystoke, Allan M. Jordan, Crispin J. Miller, Donald J. Ogilvie, Tim C.P. Somervaille, “The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem Cells” Cancer Cell, Volume 21, Issue 4, 17 April 2012, pp 473-487 doi:

Ly P. Vu, Luisa Luciani, Stephen D. Nimer. “Histone-modifying enzymes: their role in the pathogenesis of acute leukemia and their therapeutic potential” International Journal of Hematology, Volume 97, Issue 2, February 2013, pp 198-209


Because epigenetic changes are not hard-coded into the genome, they can be reversed, which makes them good candidates for development of new treatments.